Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drugs In Development, 2021

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drugs In Development, 2021

Summary

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 12 molecules. The latest report GMDHC3038TDB – Integrin Beta 7 – Drugs In Development, 2021, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease). The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2, 4 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Immunology and Infectious Disease which include indications Inflammatory Bowel Disease, Crohn's Disease (Regional Enteritis), Ulcerative Colitis, Celiac Disease, Eosinophilic Esophagitis, Graft Versus Host Disease (GVHD), Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammation and Pouchitis.

Furthermore, this report also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
  • The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Companies Mentioned

Aviara Pharmaceuticals Inc
C4X Discovery Holdings Plc
DiCE Molecules SV Inc
Genentech USA Inc
Gilead Sciences Inc
Morphic Therapeutic Inc
Polpharma Biologics SA
Progenity Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Zealand Pharma AS

Introduction
Global Markets Direct Report Coverage
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Overview
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development
Aviara Pharmaceuticals Inc
C4X Discovery Holdings Plc
DiCE Molecules SV Inc
Genentech USA Inc
Gilead Sciences Inc
Morphic Therapeutic Inc
Polpharma Biologics SA
Progenity Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Zealand Pharma AS
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles
etrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-1427 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MORF-057 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN-943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTG-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha 4 Beta 1 and Alpha 4 Beta 7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha 4 Beta 7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-10000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Products
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Product Development Milestones
Featured News & Press Releases
Sep 07, 2021: Protagonist Therapeutics appoints Scott Plevy, M.D., executive vice president and therapeutic head, gastroenterology
Jul 09, 2021: Morphic reports new data from positive phase 1 study of MORF-057, oral integrin inhibitor candidate for IBD
Jul 02, 2021: Morphic Therapeutic to host analyst and investor call on July 9, 2021
May 28, 2021: Morphic Therapeutic to present positive phase 1 data for MORF-057 at ECCO’21 Virtual Congress
Mar 01, 2021: Morphic reports positive interim results from single ascending dose phase 1 clinical trial of MORF-057
Feb 22, 2021: Morphic Therapeutic to host analyst and investor call on March 1, 2021
Jan 19, 2021: Ready-to-use self-injectable formulation of ENTYVIO (vedolizumab) now available for Canadians for the maintenance treatment of moderately to severely active Crohn's disease and ulcerative colitis
Dec 09, 2020: Takeda’s pipeline including vedolizumab has potential to contribute significantly to revenue growth over next decade
Oct 13, 2020: Takeda reports positive interim data from trial of Entyvio
Oct 12, 2020: Morphic announces presentation of new data supporting development of MORF-057 at UEG Week Virtual 2020
Sep 23, 2020: Morphic Therapeutic announces first healthy volunteers dosed in Phase 1 clinical trial of MORF-057
Sep 02, 2020: Update on the U.S. Development Program for the investigational subcutaneous formulation of ENTYVIO (vedolizumab) as a maintenance therapy in adults with moderate to severe Ulcerative Colitis
Aug 11, 2020: Roche announces mixed Phase III results of etrolizumab
Jun 23, 2020: Takeda receives U.S. FDA approval to manufacture ENTYVIO (vedolizumab) drug substance at manufacturing facility in Brooklyn Park, Minnesota
May 08, 2020: European commission approves subcutaneous formulation of Entyvio (Vedolizumab) for use as maintenance therapy in adults with moderately to severely active Ulcerative Colitis or Crohn’s Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Aviara Pharmaceuticals Inc, 2021
Pipeline by C4X Discovery Holdings Plc, 2021
Pipeline by DiCE Molecules SV Inc, 2021
Pipeline by Genentech USA Inc, 2021
Pipeline by Gilead Sciences Inc, 2021
Pipeline by Morphic Therapeutic Inc, 2021
Pipeline by Polpharma Biologics SA, 2021
Pipeline by Progenity Inc, 2021
Pipeline by Protagonist Therapeutics Inc, 2021
Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Pipeline by Zealand Pharma AS, 2021
Dormant Projects, 2021
Discontinued Products, 2021
List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings